Table 3.
Clinical correlates of progestin treatment response.
| Clinical feature | Responder (n = 43) | Nonresponder (n = 28) | Responder vs. nonresponder (P) |
|---|---|---|---|
| Demographic | |||
| Median age (IQR), years | 56 (32–64) | 59 (45–68) | 0.12 |
| Premenopausal, n (%) | 19 (44) | 8 (29) | 0.19 |
| Mean baseline weight (SD), kg | 127.8 (21.3) | 122.9 (27.4) | 0.40 |
| Mean baseline BMI (SD), kg/m2 | 48 (8) | 48 (11) | 0.98 |
| Medical status | |||
| PCOS, n (%) | 11 (26) | 5 (18) | 0.45 |
| T2DM, n (%) | 12 (28) | 10 (36) | 0.49 |
| Endometrial abnormality | |||
| Endometrial cancer, n (%) | 20 (47) | 20 (71)c | 0.04 b |
| Myometrial invasion, n (%) | 3 (7) | 3 (11) | 0.75 |
| Benign adnexal mass, n (%) | 4 (9) | 3 (11) | 0.95 |
| Weight change at 12 months | |||
| Bariatric surgery, n (%) | 16 (37) | 7 (25) | 0.28 |
| Mean weight change (95% CI), kga | −17.0 (−22.7 to −11.3) | −9.0 (−18.1 to 0.1) | 0.11 |
| Mean BMI change (95% CI), kg/m2a | −6.4 (−8.6 to −4.3) | −3.5 (−7.0 to 0.5) | 0.13 |
| Mean change total body weight (SD), %a | −12.3 (12.9) | −6.2 (14.7) | 0.09 |
| Weight loss >10% total body weight, n (%)a | 23 (53) | 6 (26) | 0.03 b |
aExcludes the n = 5 women who progressed during progestin treatment.
bSignificant at P < 0.05.
cIncludes the n = 1 participant who was treated with medroxyprogesterone acetate instead of the LNG-IUS.